John Kim
@jskim8223.bsky.social
Pulmonologist with research interests in ILD at the University of Virginia
Reposted by John Kim
Okay #MedSky #AcademicSky 📚
What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM)
Some journals invite 4-5 as default 🤯
I think 2 is sufficient, max 3 if controversy
More reviewers ➡️ less AE provides input
And SO many hours of free labour 💪
What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM)
Some journals invite 4-5 as default 🤯
I think 2 is sufficient, max 3 if controversy
More reviewers ➡️ less AE provides input
And SO many hours of free labour 💪
a man says " it 's too much " in front of a window
Alt: Schitt’s creek David says " it 's too much " in front of a window
media.tenor.com
November 2, 2025 at 9:05 PM
Okay #MedSky #AcademicSky 📚
What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM)
Some journals invite 4-5 as default 🤯
I think 2 is sufficient, max 3 if controversy
More reviewers ➡️ less AE provides input
And SO many hours of free labour 💪
What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM)
Some journals invite 4-5 as default 🤯
I think 2 is sufficient, max 3 if controversy
More reviewers ➡️ less AE provides input
And SO many hours of free labour 💪
Thrilled our paper made it to the @atsblueeditor.bsky.social ILD issue this month. Look forward to building on this work and welcome collaboration with anyone interested in subclinical pulmonary fibrosis. I think a future research area is mapping the blood-lung proteome in this context.
Associations of High Attenuation Area–Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social @atscommunity.bsky.social #medsky
🔗 tinyurl.com/da3jsx8n
@jskim8223.bsky.social @atscommunity.bsky.social #medsky
🔗 tinyurl.com/da3jsx8n
October 8, 2025 at 12:25 AM
Thrilled our paper made it to the @atsblueeditor.bsky.social ILD issue this month. Look forward to building on this work and welcome collaboration with anyone interested in subclinical pulmonary fibrosis. I think a future research area is mapping the blood-lung proteome in this context.
Reposted by John Kim
The Blue Journal thanks Riley Hannan, PhD, for his contribution to the October issue
Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social
www.atsjournals.org/doi/full/10....
Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social
www.atsjournals.org/doi/full/10....
October 3, 2025 at 5:05 PM
The Blue Journal thanks Riley Hannan, PhD, for his contribution to the October issue
Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social
www.atsjournals.org/doi/full/10....
Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social
www.atsjournals.org/doi/full/10....
Our paper is online @atsblueeditor.bsky.social identifying plasma protein markers with HAA and correlating to new-onset fibrotic/subpleural ILA. Big thanks to our collaborators in #MESA & #SPIROMICS!
www.atsjournals.org/doi/abs/10.1...
www.atsjournals.org/doi/abs/10.1...
Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities | American Journal of Respiratory and Critical Care Medicine | Articles i...
www.atsjournals.org
August 25, 2025 at 2:10 PM
Our paper is online @atsblueeditor.bsky.social identifying plasma protein markers with HAA and correlating to new-onset fibrotic/subpleural ILA. Big thanks to our collaborators in #MESA & #SPIROMICS!
www.atsjournals.org/doi/abs/10.1...
www.atsjournals.org/doi/abs/10.1...
Reposted by John Kim
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
@atscommunity.bsky.social #medsky
🔓 Open Access
🔗 tinyurl.com/4vjm9zdw
@atscommunity.bsky.social #medsky
🔓 Open Access
🔗 tinyurl.com/4vjm9zdw
July 23, 2025 at 4:11 PM
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
@atscommunity.bsky.social #medsky
🔓 Open Access
🔗 tinyurl.com/4vjm9zdw
@atscommunity.bsky.social #medsky
🔓 Open Access
🔗 tinyurl.com/4vjm9zdw
Current work playlist while writing. Any other music #PCCM are putting on in the background for work? @kaminskimed.bsky.social @kerrijohannson.bsky.social @ipfdoc.bsky.social @drdayjee.bsky.social @emilyfri.bsky.social @drpujamehta1.bsky.social?
open.spotify.com/playlist/37i...
open.spotify.com/playlist/37i...
Sinners Official Playlist
Playlist · Spotify · 74 items · 50.9K saves
open.spotify.com
April 30, 2025 at 1:17 PM
Current work playlist while writing. Any other music #PCCM are putting on in the background for work? @kaminskimed.bsky.social @kerrijohannson.bsky.social @ipfdoc.bsky.social @drdayjee.bsky.social @emilyfri.bsky.social @drpujamehta1.bsky.social?
open.spotify.com/playlist/37i...
open.spotify.com/playlist/37i...
Reposted by John Kim
🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival
🔗 www.thelancet.com/journals/lan...
📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival
🔗 www.thelancet.com/journals/lan...
April 29, 2025 at 7:38 AM
🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival
🔗 www.thelancet.com/journals/lan...
📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival
🔗 www.thelancet.com/journals/lan...
Reposted by John Kim
Delighted to share our new study evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with #PRS of IPF.
🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival
🔗 www.thelancet.com/journals/lan...
📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival
🔗 www.thelancet.com/journals/lan...
April 29, 2025 at 8:42 AM
Delighted to share our new study evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with #PRS of IPF.
Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Fibrosis: cross-organ biology and pathways to development of innovative drugs - Nature Reviews Drug Discovery
Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in fibrotic conditions across organs, as wel...
www.nature.com
March 22, 2025 at 11:11 AM
Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by John Kim
Excited to post my first #skySplain about our recent work published yesterday in Nature Genetics! www.nature.com/articles/s41.... One of the first authors of this study - Annika Vannan – actually wrote this breakdown, but she's not yet over here on bluesky and asked me to post!
Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis - Nature Genetics
Xenium spatial transcriptomic profiling of pulmonary fibrosis characterizes cell composition dynamics and histopathological features associated with the disease.
www.nature.com
February 4, 2025 at 2:11 PM
Excited to post my first #skySplain about our recent work published yesterday in Nature Genetics! www.nature.com/articles/s41.... One of the first authors of this study - Annika Vannan – actually wrote this breakdown, but she's not yet over here on bluesky and asked me to post!
Reposted by John Kim
Genomic and Serological Rheumatoid Arthritis Biomarkers, MUC5B Promoter Variant, and Interstitial Lung Abnormalities
@atscommunity.bsky.social #medsky
🔗 tinyurl.com/mr4cke25
@atscommunity.bsky.social #medsky
🔗 tinyurl.com/mr4cke25
January 14, 2025 at 7:54 PM
Genomic and Serological Rheumatoid Arthritis Biomarkers, MUC5B Promoter Variant, and Interstitial Lung Abnormalities
@atscommunity.bsky.social #medsky
🔗 tinyurl.com/mr4cke25
@atscommunity.bsky.social #medsky
🔗 tinyurl.com/mr4cke25
Reposted by John Kim
🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
January 4, 2025 at 6:53 PM
🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Just out in @atsblueeditor.bsky.social 🫁
www.atsjournals.org/doi/abs/10.1...
State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions
Reposted by John Kim
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
December 21, 2024 at 6:52 AM
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
Reposted by John Kim
The Blue Journal thanks Catherine L. Debban, PhD, for her contribution to the December 15 issue
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
www.atsjournals.org/doi/full/10....
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
www.atsjournals.org/doi/full/10....
December 18, 2024 at 5:33 PM
The Blue Journal thanks Catherine L. Debban, PhD, for her contribution to the December 15 issue
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
www.atsjournals.org/doi/full/10....
Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
www.atsjournals.org/doi/full/10....
Reposted by John Kim
Question for intensivists regarding theoretical vs observed risk tolerance. How much consideration or pause (if any) are you given when starting inhaled pulmonary vasodilators for refractory hypoxemia if the patient has concurrent left heart dysfunction?
#MedSky #EMIMCC #CritCareSky #CardioSky
#MedSky #EMIMCC #CritCareSky #CardioSky
December 15, 2024 at 7:31 AM
Question for intensivists regarding theoretical vs observed risk tolerance. How much consideration or pause (if any) are you given when starting inhaled pulmonary vasodilators for refractory hypoxemia if the patient has concurrent left heart dysfunction?
#MedSky #EMIMCC #CritCareSky #CardioSky
#MedSky #EMIMCC #CritCareSky #CardioSky
Reposted by John Kim
last night, Hallie Prescott had her NEJM review on sepsis released: www.nejm.org/doi/full/10....
Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan
Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan
Sepsis and Septic Shock | NEJM
Sepsis is a life-threatening, heterogeneous disorder involving a dysregulated immune response to infection. Research to identify subtypes and targeted therapies for host dysregulation is ongoing.
www.nejm.org
December 6, 2024 at 2:19 AM
last night, Hallie Prescott had her NEJM review on sepsis released: www.nejm.org/doi/full/10....
Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan
Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan
Reposted by John Kim
For the new BlueSky members who have left #ILDTwitter I’ve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if I’ve missed you and I’ll add you 🫁😊
#CurePF #CureIPF #ILD
go.bsky.app/8u4KcNo
#CurePF #CureIPF #ILD
go.bsky.app/8u4KcNo
November 14, 2024 at 3:22 AM
For the new BlueSky members who have left #ILDTwitter I’ve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if I’ve missed you and I’ll add you 🫁😊
#CurePF #CureIPF #ILD
go.bsky.app/8u4KcNo
#CurePF #CureIPF #ILD
go.bsky.app/8u4KcNo